Skip to content
type1.science

Medtronic Simplera (standalone)

Medtronic

Medtronic's first disposable, all-in-one CGM — half the size of its older Guardian sensors, factory-calibrated, 7-day wear. It now supports the InPen-based MiniMed Go injection system in both Europe and the US; the current US label limits the Simplera configuration to adults 18+. Independent data put Simplera's accuracy behind Dexcom G7 and Libre 3.

Available nowRegulator-approvedcgm

The scorecard

Accuracy60

Manufacturer MARD ~10.2% vs venous reference, but the only independent head-to-head found 11.6% (venous YSI) rising to 16.6% (capillary) — and two further real-world studies reported MARDs of 13.8% (exercise) and 19.9% (flight), consistently behind G7 and Libre 3.[1]

Low lag55

Interstitial lag like all sensors; independent data show it lags and reads low during fast-rising glucose (MARD ~20% when rising >2 mg/dL/min), a meaningful weakness post-meal.[1]

Interoperability30

Standalone Simplera supports the InPen-based MiniMed Go smart MDI system in Europe and the US. It does not drive commercial AID or an open-source loop; the pump sensor is the separate Simplera Sync.[4]

Sensor lifespan60

7-day wear — shorter than Libre's 14 days or the 15-day G7; independent sensor-survival to day 7 was only ~81.5%.[1]

No calibration88

Factory-calibrated; no fingersticks required. Optional manual calibration is available but not needed for normal use.[1]

Alerts & prediction75

Configurable high/low alerts plus predictive "alert before low" up to 60 min ahead, on phone and Apple Watch; in the independent head-to-head its low detection was class-leading (93.1% of true lows, vs 73–80% for G7 and Libre 3) while its high detection (84.6%) trailed both rivals (~99.7%).[1]

Form factor82

Disposable all-in-one sensor about half the size of the Guardian 4, worn on the upper arm, no overtape; 2-hour warm-up.[5]

Ketone sensing0

No ketone sensing — glucose only.

Access & cost55

CE-marked and sold across Europe, FDA-authorized in August 2024, and available through a region-specific ecosystem. Current US pages list Simplera as a MiniMed Go sensor and offer an InPen-plus-Simplera start pathway for adults 18+, while the MiniMed Go order bundle foregrounds Instinct. Local access and coverage still vary.[11]

The full picture

The Medtronic Simplera (standalone) is Medtronic's first disposable, all-in-one continuous glucose monitor (CGM) — a small square sensor you press onto the back of your upper arm with a one-step applicator, with no separate transmitter and no overtape. It's about half the size of Medtronic's older Guardian 4 sensor.1 It reads glucose every five minutes and streams it by Bluetooth to a phone app and Apple Watch.2 Two versions exist and it's important not to confuse them: the standalone Simplera here supports the InPen-based MiniMed Go smart MDI system in Europe and the US, while a separate sensor, Simplera Sync, drives the MiniMed 780G pump.341

Accuracy — read this carefully. Medtronic's own data put the MARD (mean absolute relative difference — lower is better) at about 10.2% against a venous lab reference.5 But the only manufacturer-independent head-to-head study — 24 adults with type 1 wearing Simplera, Dexcom G7 and FreeStyle Libre 3 at once — found Simplera less accurate than both rivals: MARD 11.6% against the venous YSI analyser, rising to 13.9% against another venous method and 16.6% against a fingerstick meter, versus roughly 9–12% for G7 and Libre 3.5 Two further real-world studies reinforced the gap: a MedARD of 13.8% around exercise and 19.9% during air travel, both significantly worse than G7 and Libre 3.67 Accuracy is worst in the first 12 hours (MARD ~20%) and when glucose is rising fast, where it tends to read low.5 The redeeming strength: Simplera detected lows better than either competitor (93% of true lows caught), so it leans toward catching hypoglycemia at the cost of more false alarms.5

Wear, warm-up & calibration. Each sensor lasts 7 days — shorter than Libre's 14 or the 15-day G7 — with a 2-hour warm-up, and it is factory-calibrated so no fingersticks are required (an optional manual calibration exists but isn't needed).52 Independent testing saw only ~82% of sensors survive the full 7 days.5

Alerts & app. The app gives configurable high/low alerts plus a predictive "alert before low" up to 60 minutes ahead, a fixed urgent-low alert at 64 mg/dL, and a live Time-in-Range view; alerts mirror to an Apple Watch.42

What it works with. The standalone sensor connects to the Simplera app and the InPen-based MiniMed Go smart MDI system in Europe and the US.234 It does not drive any commercial automated insulin delivery (AID) system and is not supported by any open-source/DIY loop — that is the separate Simplera Sync with the 780G.1 This narrow, region-dependent ecosystem is its biggest practical limitation.

Ketones. None — it senses glucose only, like all current mainstream CGMs.

Who it's for. Labeling is regional. The current US MiniMed Go page lists Simplera for adults 18 and older; its Instinct configuration has a younger label.4 In Europe, MiniMed Go with Simplera is approved from age 7, and for ages 2–6 with adult caregiver supervision.3 (The pump-driving Sync sensor is cleared from age 7.)8

Access & cost. Simplera has been CE-marked and sold across Europe since 2023–24 and won FDA approval on 7 August 2024.81 MiniMed Go with Simplera began a gradual European rollout on 25 February 2026.3 In the US, MiniMed's current Smart MDI page offers a get-started pathway for InPen with Simplera, while the current MiniMed Go order flow foregrounds an initial supply of Instinct sensors.94 Both current pages nevertheless list Simplera as a supported US configuration for adults 18+, so that compatibility is current rather than pending. Availability and coverage still vary by region.

References

  1. Medtronic. Medtronic announces FDA approval of Simplera™ CGM and global partnership with Abbott. Medtronic News (2024). https://news.medtronic.com/2024-08-07-Medtronic-announces-FDA-approval-of-Simplera-TM-CGM-and-global-partnership-with-Abbott ↩ ↩2 ↩3 ↩4

  2. Medtronic. Simplera™ — App Store listing. Apple App Store. https://apps.apple.com/be/app/simplera/id1666540280 ↩ ↩2 ↩3 ↩4

  3. MiniMed. European commercial launch of MiniMed Go with Simplera (25 February 2026) — gradual rollout; age 7+, or ages 2–6 with adult caregiver supervision. https://news.minimed.com/2026-02-25-Medtronic-begins-EMEA-commercial-launch-of-MiniMed-Go-Smart-MDI-system-with-Simplera-sensor ↩ ↩2 ↩3 ↩4

  4. MiniMed. MiniMed Go system — current US compatibility and specifications (lists Instinct and Simplera as the two compatible sensors; Simplera configuration for ages 18+). Retrieved 8 August 2026. https://www.minimed.com/en-us/products/minimed-go-system ↩ ↩2 ↩3 ↩4 ↩5

  5. Eichenlaub M, et al. Performance of Three Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes. Journal of Diabetes Science and Technology (2025). PMID 39902649. https://doi.org/10.1177/19322968251315459 ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  6. Sanfilippo S, et al. Performance of three simultaneously used rtCGM systems around a physically active weekend camp in adults with type 1 diabetes. Diabetes, Obesity & Metabolism (2025). PMID 41417319. https://doi.org/10.1111/dom.70369 ↩

  7. Meçani R, et al. Performance of continuous glucose monitoring systems (CGMs) during commercial flights in T1DM. Diabetes, Obesity & Metabolism (2026). PMID 41480660. https://doi.org/10.1111/dom.70418 ↩

  8. Medtronic. Medtronic Diabetes announces world's first approval for MiniMed™ 780G System with Simplera Sync™ disposable, all-in-one sensor. Medtronic News (2024). https://news.medtronic.com/2024-01-08-Medtronic-Diabetes-announces-worlds-first-approval-for-MiniMed-TM-780G-System-with-Simplera-Sync-TM-disposable,-all-in-one-sensor ↩ ↩2

  9. MiniMed. Smart MDI system — InPen with Simplera (current US get-started pathway; components sold separately). Retrieved 8 August 2026. https://www.minimed.com/en-us/products/smart-mdi-system ↩

Sources

  1. [1]Performance of Three Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes · peer-reviewed · 2025-02-04 — First manufacturer-independent head-to-head (n=24, T1D) of Libre 3, Dexcom G7 and Medtronic Simplera. Simplera MARD 11.6% (YSI venous), 13.9% (Cobas venous), 16.6% (Contour Next capillary); first-12h MARD 20.0%; 7-day survival 81.5%; factory-calibrated with optional (unused) calibration. PMID 39902649 / PMC11795573. Retrieved via PubMed.
  2. [2]Performance of three simultaneously used rtCGM systems around a physically active weekend camp in adults with type 1 diabetes · peer-reviewed · 2025-12-19 — Real-world lab + home study (n=20). Median ARD: G7 8.4%, Libre 3 7.5%, Simplera 13.8% (significantly worse than both, p<0.0001). PMID 41417319. Retrieved via PubMed.
  3. [3]Performance of continuous glucose monitoring systems (CGMs) during commercial flights in T1DM · peer-reviewed · 2026-01-02 — In-flight/ground pilot study (n=20). Overall MARD: G7 9.5%, Libre 3 9.6%, Simplera 19.9%; %20/20 agreement 63.6% (vs ~90% for G7/Libre). PMID 41480660. Retrieved via PubMed.
  4. [4]MiniMed Go system — current US sensor compatibility and specifications · manufacturer — Current US page defines MiniMed Go as InPen plus the app and either Instinct or Simplera. It lists Simplera for ages 18+, along with its alert ranges and performance specifications. Retrieved 8 August 2026.
  5. [5]Medtronic announces FDA approval of Simplera CGM and global partnership with Abbott · manufacturer · 2024-08-07 — FDA approval of the standalone Simplera CGM on 7 Aug 2024; "first disposable, all-in-one CGM, half the size of previous Medtronic CGMs," no overtape; CE-marked in Europe; designed to work with the InPen Smart MDI system.
  6. [6]Medtronic receives FDA clearance for new InPen app, paving the way for its Smart MDI system launch with Simplera CGM · manufacturer · 2024-11-20 — InPen app FDA clearance 20 Nov 2024; Smart MDI = InPen + Simplera CGM; limited US market release beginning with existing standalone CGM and InPen customers, then broad launch.
  7. [7]MiniMed Go with Simplera begins European commercial rollout · manufacturer · 2026-02-25 — Gradual European launch from February 2026. MiniMed Go combines InPen and Simplera in one app; European approval is age 7+, or ages 2–6 with adult caregiver supervision.
  8. [8]MiniMed confirms US launch of MiniMed Go · manufacturer · 2026-05-27 — Says MiniMed Go launched in the United States during the week of 25 May 2026. The launch announcement foregrounded the Instinct configuration; current compatibility is documented separately on the live product page.
  9. [9]Medtronic Diabetes announces world's first approval for MiniMed 780G System with Simplera Sync disposable, all-in-one sensor · manufacturer · 2024-01-08 — Confirms standalone Simplera received CE Mark (Sept 2023) for use with the InPen; the pump-driving Simplera Sync got CE Mark / first approval with MiniMed 780G in Jan 2024 (ages 7+, 6-day wear).
  10. [10]Simplera app — App Store listing · manufacturer — Standalone Simplera app: real-time SG, predictive alerts, Time-in-Range, no calibrations; iOS 15+, Apple Watch (watchOS 9+); pairs only with the Simplera sensor; available across European markets. Retrieved Jun 2026.
  11. [11]US Smart MDI system — InPen plus Simplera access · manufacturer — Current US page presents InPen with Simplera, provides a get-started pathway, and states that the components are sold separately. Simplera is indicated for adults 18+. Retrieved 8 August 2026.